Ameriprise
APGE

Ameriprise’s Apogee Therapeutics APGE Stock Holding History

Ameriprise’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Sell
15,490
-54,398
-78% -$4.9M ﹤0.01% 3065
2026
Q1 		$5.88M Sell
69,888
-53,012
-43% -$3.85M ﹤0.01% 2327
2025
Q4 		$9.28M Buy
122,900
+19,748
+19% +$1.24M ﹤0.01% 1970
2025
Q3 		$4.1M Sell
103,152
-52,956
-34% -$2.02M ﹤0.01% 2579
2025
Q2 		$6.78M Buy
156,108
+59,782
+62% +$2.27M ﹤0.01% 2112
2025
Q1 		$3.6M Buy
96,326
+90,616
+1,587% +$3.5M ﹤0.01% 2546
2024
Q4 		$259K Buy
+5,710
New +$291K ﹤0.01% 3776

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Ameriprise's APGE Position: Q2 2026 in Review

Ameriprise reduced its Apogee Therapeutics (APGE) stake by 78% in Q2 2026, selling an estimated $4.9M and leaving 15,490 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Ameriprise first reported a position in APGE in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.28M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Ameriprise held 15,490 shares of Apogee Therapeutics worth $2.06M as of Q2 2026.
  • Ameriprise sold 54,398 Apogee Therapeutics shares in Q2 2026, an estimated $4.9M.
  • Apogee Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3065 holding.
  • Ameriprise first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Ameriprise's Apogee Therapeutics position peaked at $9.28M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.